Consequently, GPC3 has been widely recognized as a potential diagnostic and therapeutic target for LC.[138] One study evaluated liposomes coated with anti‐GPC3 antibodies (GV‐Lipo/SF/DT) for the delivery of Sor in LC treatment. The gene discussed is GPC3; the disease is laryngotracheoesophageal cleft.